Extend Biosciences Inc

pSivida Corporation is a global bio-nanotech company. It has expertise in the development of drug delivery products for the health care sector, especially in ophthalmology and oncology. The company has developed products under the Vitrasert and Retisert brands for the treatment of chronic eye diseases. pSivida Corporation s products are manufactured and sold by global ophthalmology company, Bausch & Lomb. The company has a partnership with Alimera Sciences to develop products for the treatment of diabetic macular edema and other ophthalmic applications, as well as inoperable pancreatic cancer. It conducts clinical trials in the United States, Canada, Europe and India. pSivida Corporation also has partnerships with Pfizer, QinetiQ and the former United Kingdom Government Defence Evaluation & Research Agency.

Opexa Therapeutics is a biotechnology company that specializes in the development of patient-specific cellular therapies for the treatment of autoimmune diseases, such as multiple sclerosis and diabetes. It offers Tovaxin, which is a vaccine for early relapsing multiple sclerosis. The company also offers an adult stem cell program that enables the production of multipotent cells generated from patients white blood cells and provides means to differentiate these stem cells into other tissue types. Opexa Therapeutics offers solutions that minimize the threat of treatment rejection. It operates clinical advisory boards for multiple sclerosis and diabetes that take care of the supervision of related procedures. The company provides products to target individual s disease progression and modification.

Lumira DX is a global healthcare company that specializes in providing high sensitivity point-of-care diagnostic systems. Their innovative LumiraDx Platform combines a portable instrument, microfluidic test strip, and seamless digital connectivity to deliver lab-comparable performance and real-time results at the point of care. With a broad test menu and improved economic value, Lumira DX aims to strengthen community-based healthcare and make affordable diagnostics accessible to healthcare providers worldwide. Lumira DX's cutting-edge technology offers a range of assay capabilities, including COVID-19 antigen and antibody tests, as well as over 30 other tests across various assay technologies. Their cloud-based platform empowers healthcare professionals with effortless data reporting, analytics, and decision support, making it suitable for emergency departments, primary care, health clinics, and retail pharmacies. With a focus on better health experiences, outcomes, and cost control, Lumira DX is committed to supporting healthier lives for individuals, communities, and society as a whole.Generated from the website